UBS sets USD 48 target for uniQure stock as it trades 1.60 percent lower

Published on 10/15/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 5.84 million in the second quarter versus USD 5.26 million. uniQure stock costs EUR 18.50 on October 15, 2026, 1.60 percent below Xetra close.

Analyst coverage and clinical evidence

UBS set a USD 48.00 target from USD 27.00 on October 14, 2026.
AMT-130 showed 80 percent slower progression at 36 months on September 29, 2026.
uniQure stock trades at EUR 18.50 at 12:30 p.m. CEST at Lang & Schwarz on October 15, 2026, minus 1.60 percent below the Xetra close of October 14, 2026.
Second-quarter revenue was USD 5.84 million versus USD 5.26 million a year earlier.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure N.V. (ISIN NL0010696654) trades at EUR 18.50 at Lang & Schwarz on October 15, 2026 at 12:30 p.m. CEST, down 1.60 percent versus the Xetra close of October 14, 2026 at EUR 18.80. UBS began coverage on October 14 with a Buy rating and a USD 48.00 price target, up from USD 27.00, according to Markets Insider.

UBS sees a USD 48 target

The UBS view arrives after mixed long-term evidence for AMT-130, uniQure's investigational Huntington's disease therapy. Markets Insider reported that the company generated USD 5.84 million of revenue in the second quarter ended June 30, 2026, compared with USD 5.26 million in the year-earlier quarter. GAAP net loss widened to USD 81.06 million from USD 37.72 million.

The recent chronology is clear: uniQure submitted its AMT-130 biologics license application on September 2, 2026; it reported 80 percent slowing on the composite measure and 67 percent slowing on Total Functional Capacity at 36 months on September 29, 2026; and UBS initiated coverage with a USD 48.00 target from USD 27.00 on October 14, 2026. The clinical release is available through Seeking Alpha.

What does the evidence mean?

The 36-month result supports the regulatory case, but the 48-month cUHDRS result showed 44 percent slowing and did not reach statistical significance, while Total Functional Capacity showed 61 percent slowing. Business Wire reported that the 48-month cUHDRS result was smaller than the 36-month result. The contrast leaves regulatory durability as the key investor question.

Next reporting date

The next scheduled reporting date is November 9, 2026, according to Insider Buying. Investors will have another chance to assess cash use, development spending and the path toward the confirmatory study.

Stock stays below recent levels

At EUR 18.50, the Lang & Schwarz quote was 1.60 percent below the Xetra close of October 14, 2026 at EUR 18.80. The primary listing is on Nasdaq, where the stock closed at USD 21.28 on October 14, 2026.

The further course of trading is shown by the continuously updated real-time quote of uniQure stock.